Novartis holds back the copycat brigade's attack on its top drug franchise — for now
A federal judge has put a generic challenge to Novartis’ blockbuster multiple sclerosis drug Gilenya on hold while a patent fight plays out in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
